Mathias K. Fehr

Frauenfeld, TG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Long-term cosmetic outcome after intraoperative radiotherapy boost with low-energy X-rays in breast-conserving therapy: a pooled cohort analysis of the TARGIT-BQR and ROKSM trials.

Long-term cosmetic outcome after intraoperative radiotherapy boost with low-energy X-rays in breast-conserving therapy: a pooled cohort analysis of the TARGIT-BQR and ROKSM trials.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: July 23, 2025

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer.

Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: February 15, 2025

Sentinel SENECA risk factors for unsuccessful bi-lateral sentinel lymph node mapping in endometrial cancer.

Sentinel SENECA risk factors for unsuccessful bi-lateral sentinel lymph node mapping in endometrial cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: January 13, 2025

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).

Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).

Journal: Geburtshilfe und Frauenheilkunde

Published: November 25, 2024

Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?

Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?

Journal: Current oncology (Toronto, Ont.)

Published: July 15, 2024

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.

Journal: JAMA oncology

Published: April 25, 2024

Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.

Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.

Journal: JAMA surgery

Published: July 19, 2023

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Journal: Breast cancer research and treatment

Published: March 17, 2023

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

Journal: Journal of geriatric oncology

Published: February 02, 2022

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients.

Journal: Endocrine oncology (Bristol, England)

Published: January 23, 2022

Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial.

Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial.

Journal: BMJ open

Published: September 03, 2021

Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).

Journal: Breast (Edinburgh, Scotland)

Published: July 30, 2021

Showing 1-12 of 32

Last Updated: 09/26/2026